Integrated BioPharma, Inc. (INBP) released its financial results for the quarter ended September 30, 2026, reporting a significant decline in revenue compared to the prior year period. For the three months ended September 30, 2026, the company recorded total revenue of $9.9 million. This figure represents a decrease of $2.8 million, or approximately 22.0%, when compared to the $12.7 million in revenue generated during the same period in 2025.
Despite the revenue decrease, the company reported an operating loss of $1.0 million for the quarter ended September 30, 2026. This marks a shift from the previous year, where the company recorded operating income of $0.2 million for the quarter ended September 30, 2025. The company also reported a net loss of approximately $0.7 million for the most recent quarter, compared to net income of approximately $0.1 million in the prior year.
On a per-share basis, the company reported a diluted net loss of $(0.02) per common share for the quarter ended September 30, 2026. This compares to diluted net income of $0.00 per share for the quarter ended September 30, 2025. The company’s Co-Chief Executive Officers, Riva Sheppard and Christina Kay, noted that the decline in revenue was accompanied by a concentration in the company's Contract Manufacturing Segment, where revenue from the two largest customers represented approximately 88% and 87% of total revenue in the quarters ended September 30, 2026 and 2025, respectively.
